1072467-37-8

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 3162-29-6 1-(benzo[d][1,3]dioxol-6-yl)ethanone 
• 30879-49-3 1-(5-hydroxy-2-nitrophenyl)ethan-1-one 
• 75889-41-7 6-ethylbenzo[d][1,3]dioxole-5-carbaldehyde 
• 60373-70-8 3,4-(methylenedioxy)-ethylbenzene 
• 1159608-46-4 ethyl-(E)-3-(3-(5-hydroxy-2-nitrophenyl)-3-oxoprop-1-en-1-yl)benzoate 
• 1159608-45-3 (E)-3-(3-(5-hydroxy-2-nitrophenyl)-3-oxoprop-1-en-1-yl)benzoic acid 
• 1159608-54-4 ethyl 3-[3-(ethoxycarbonyl)benzyl]-1-[(6-ethylbenzo[d][1,3]dioxol-5-yl)methyl]-6-hydroxy-4-oxo-1,4-dihydroquinoline-2-carboxylate 

Relevant academic research and scientific papers

Design, synthesis and evaluation of 1,3,6-trisubstituted-4-oxo-1,4-dihydroquinoline-2-carboxylic acid derivatives as ETA receptor selective antagonists using FRET assay

The endothelin axis and in particular the two receptor subtypes, ETA and ETB, are under investigation for the treatment of various diseases such as pulmonary arterial hypertension, fibrosis, renal failure and cancer. Previous work in

Synthesis and pharmacological activity of 1,3,6-trisubstituted-4-oxo-1,4- dihydroquinoline-2-carboxylic acids as selective ETA antagonists

A series of 1,3,6-trisubsituted-4-oxo-1,4-dihyroquinoline-2-carboxylic acid analogs (2a-m) were designed and synthesized and their pharmacological activity determined, with the objective to better understand their SAR as potential ETA selective inhibitors. Most of the compounds displayed significant ETA antagonist activity having IC50 for inhibition of binding of the [125I]ET-1 to ETA receptor A antagonism over ETB receptor. Based on the in vitro results, SAR of this series of compounds requires an alkoxy substituent at the 6-position to be a straight and saturated chain up to three carbons long, since substitution of unsaturated and branched alkyloxy groups results in decrease in ETA antagonist activity. In this series, compound 2c (6-O-n-propyl analog) was found to be most potent (IC 50 = 0.11 nM) with ETB/ETA selectivity of 8303.

Synthesis of 1,3,6-trisubstituted-2-carboxyquinol-4-ones as selective ET A antagonists and their use as medicaments

The invention discloses the composition and preparation of various 1,3,6-trisubstituted-2-carboxy-quinol-4-ones of the formula 1 where R is H, alkyl, haloalkyl or hydroxyalkyl, R′ is alkyl, nitro, halogen or NR2′″ where R′″ is alkyl or cycloalk